Physician
Emergency Medicine
Dr. Donald J. Tindall Jr., MD
|
|
Give Review
Donald J. Tindall Jr. is an expert in the field of Emergency Medicine. He went to medical school at Loma Linda University School of Medicine. Dr. Donald J. Tindall Jr. is a published MD. He has 97 papers published. The most current publication "Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation." Doctor Donald J. Tindall Jr., MD accepts all Medicare patients.
Publications
- Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation.
- Are androgen receptor variants a substitute for the full-length receptor?
- The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells.
- Preclinical Evaluation of the Supercritical Extract of Azadirachta Indica (Neem) Leaves In Vitro and In Vivo on Inhibition of Prostate Cancer Tumor Growth.
- Androgen receptor: past, present and future.
- Androgens Regulate TRAIL-induced Cell death in Prostate Cancer Cells via Multiple Mechanisms.
- Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance.
- Androgen Receptor Rediscovered: The New Biology and Targeting the Androgen Receptor Therapeutically.
- Alternatively spliced androgen receptor variants.
- Targeting 5α-reductase for prostate cancer prevention and treatment.
- Androgens repress expression of the f-box protein Skp2 via p107 dependent and independent mechanisms in LNCaP prostate cancer cells.
- Novel Molecular Targets of Azadirachta indica Associated with Inhibition of Tumor Growth in Prostate Cancer.
- Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer.
- Identification of a clinically relevant androgen-dependent gene signature in prostate cancer.
- Regulation of FOXO protein stability via ubiquitination and proteasome degradation.
- Androgen action during prostate carcinogenesis.
- Androgen action in prostate cancer.
- Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer.
- Differential regulation of steroid nuclear receptor coregulator expression between normal and neoplastic prostate epithelial cells.
- FAVL elevation in human tumors disrupts Fanconi anemia pathway signaling and promotes genomic instability and tumor growth.
- New developments in the medical management of prostate cancer.
- Androgen regulation of gene expression.
- Oxidative stress and DNA methylation in prostate cancer.
- Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression.
- Effects of the 5 alpha-reductase inhibitor dutasteride on gene expression in prostate cancer xenografts.
- Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter.
- Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81.
- Deficiencies in Chfr and Mlh1 synergistically enhance tumor susceptibility in mice.
- Androgen receptor abnormalities in castration-recurrent prostate cancer.
- Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1.
- Hypermethylation of genes for diagnosis and risk stratification of prostate cancer.
- Unraveling the complexities of androgen receptor signaling in prostate cancer cells.
- Androgen modulation of coregulator expression in prostate cancer cells.
- Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosis.
- Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancer.
- Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity.
- Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression.
- Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.
- The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
- The role of the transcriptional coactivator p300 in prostate cancer progression.
- Androgen receptor structural and functional elements: role and regulation in prostate cancer.
- Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex.
- Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer.
- Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells.
- Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride.
- Pursuing the androgen pathway on the quest to control prostate cancer.
- CDK2 and FOXO1: a fork in the road for cell fate decisions.
- Androgen deprivation increases p300 expression in prostate cancer cells.
- Truncating variants in p53AIP1 disrupting DNA damage-induced apoptosis are associated with prostate cancer risk.
- DHEA in elderly women and DHEA or testosterone in elderly men.
- CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage.
- Molecular regulation of androgen action in prostate cancer.
- Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines.
- Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells.
- Prostate cancer cells use genetic and epigenetic mechanisms for progression to androgen independence.
- PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer.
- p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6.
- Regulation of expression of the early growth response gene-1 (EGR-1) in malignant and benign cells of the prostate.
- Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation.
- p300 modulates nuclear morphology in prostate cancer.
- Androgens and prostate cancer: are the descriptors valid?
- Gene expression in prostate cancer cells treated with the dual 5 alpha-reductase inhibitor dutasteride.
- Gluthatione-S-transferase P1 polymorphism I105V in familial and sporadic prostate cancer.
- Mechanisms of androgen-refractory prostate cancer.
- Of mice, men, and hormones.
- Androgens negatively regulate forkhead transcription factor FKHR (FOXO1) through a proteolytic mechanism in prostate cancer cells.
- Transformation of NIH 3T3 cells by enhanced PAR expression.
- Inverse association between prostate cancer and the use of calcium channel blockers.
- The cytoskeleton differentially localizes the early growth response gene-1 protein in cancer and benign cells of the prostate.
- p300 in prostate cancer proliferation and progression.
- Identification and characterization of a consensus DNA binding element for the zinc finger transcription factor TIEG/EGRalpha.
- Mutations in CHEK2 associated with prostate cancer risk.
- p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6.
- Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells.
- The role of the androgen receptor in prostate cancer.
- Modulation of Androgen Receptor by FOXA1 and FOXO1 Factors in Prostate Cancer.
- Posttranslational modification of the androgen receptor in prostate cancer.
- The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous...
- Symposium on androgen action in prostate cancer.
- Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
- Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.
- Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
- A comparison of the adrenal responses to hypoglycemia, metyrapone and ACTH.
- The role of androgens and the androgen receptor in prostate cancer.
- TGF-betal/Smad signaling in prostate cancer.
- Evaluation of familial clustering of breast and prostate cancer in the Minnesota Breast Cancer Family Study.
- Decline in the overall incidence of regional-distant prostate cancer in Olmsted County, MN, 1980-2000.
- Regulation of androgen receptor signaling in prostate cancer.
- Dynamic FoxO transcription factors.
- FOXO factors: a matter of life and death.
- Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
- Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder.
- Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells.
- Effect of dutasteride on the risk of prostate cancer.
- Androgen receptor signaling in prostate cancer development and progression.
- Mechanism of lymph node metastasis in prostate cancer.
Schools
Loma Linda University
Florida Hospital Med Center
Loma Linda University Med Center
Doctors Specialties
- Emergency Medicine
Accepted Insurances
Education
-
Loma Linda University -
Loma Linda University School of Medicine
Hospital
-
Florida Hospital -
Mayo Clinic - Rochester, Minnesota
Helpful Reviews
Similar Doctors
|
|
Dr. Jose J. Castillo, MD
 This Doctor is OpenDoctor Recommended.
|